P

Inventor

DOMI ARBAN

US17 patents
⚠️ This page may combine multiple inventors who share the name “DOMI ARBAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

GEOVAX INC

12 patents
US11311612B2Apr 26, 2022

Compositions and methods for generating an immune response to treat or prevent malaria

GEOVAX INC6 citations83
US11857611B2Jan 2, 2024

Compositions and methods for generating an immune response to treat or prevent malaria

GEOVAX INC2 citations71
US11052148B2Jul 6, 2021

Compositions and methods for generating an immune response to hepatitis B virus

GEOVAX INC2 citations70
US11413341B2Aug 16, 2022

Vaccinia viral vectors encoding chimeric virus like particles

GEOVAX INC1 citations69
US11278607B2Mar 22, 2022

Compositions and methods for generating an immune response to a tumor associated antigen

GEOVAX INC2 citations69
US12329808B2Jun 17, 2025

Compositions and methods for generating an immune response to treat or prevent malaria

GEOVAX INC0 citations60
US11638750B2May 2, 2023

Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein

GEOVAX INC0 citations60
US12247214B2Mar 11, 2025

Vaccinia viral vectors encoding chimeric virus like particles

GEOVAX INC0 citations59
US12370249B2Jul 29, 2025

Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40)

GEOVAX INC0 citations58
US11896657B2Feb 13, 2024

Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus glycoprotein (GP) and matrix protein (VP40)

GEOVAX INC0 citations58
US12577589B2Mar 17, 2026

Vaccines and uses thereof to induce an immune response to SARS-CoV2

GEOVAX INC0 citations55
US11701418B2Jul 18, 2023

Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)

GEOVAX INC0 citations49

INT AIDS VACCINE INITIATIVE

3 patents

UNIV GEORGIA STATE RES FOUND

1 patent

US HEALTH

1 patent